Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Karuna Therapeutics, Inc. stock logo
KRTX
Karuna Therapeutics
$329.83
$327.01
$158.38
▼
$329.99
$12.58B1.18832,048 shsN/A
BeOne Medicines Ltd. - Sponsored ADR stock logo
ONC
BeOne Medicines
$412.35
-1.0%
$369.18
$253.95
▼
$424.73
$45.34B0.63322,642 shs84,293 shs
Royalty Pharma PLC stock logo
RPRX
Royalty Pharma
$68.67
-0.9%
$61.51
$37.31
▼
$70.37
$39.42B0.363.42 million shs1.44 million shs
Zoetis Inc. stock logo
ZTS
Zoetis
$83.61
-0.3%
$76.28
$68.77
▼
$132.49
$33.96B0.675.43 million shs1.72 million shs
7 Best Space Stocks to Own in 2026 Cover

The space race is growing fast, and you don’t have to have gotten in early on SpaceX to profit. This report shows seven space stocks you can buy today that may grow as rockets, satellites, defense, space internet, and new space technology become more important.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Karuna Therapeutics, Inc. stock logo
KRTX
Karuna Therapeutics
0.00%0.00%0.00%0.00%0.00%
BeOne Medicines Ltd. - Sponsored ADR stock logo
ONC
BeOne Medicines
0.00%+2.35%+12.87%+14.90%+13.86%
Royalty Pharma PLC stock logo
RPRX
Royalty Pharma
0.00%+2.99%+13.70%+16.59%+76.99%
Zoetis Inc. stock logo
ZTS
Zoetis
0.00%+5.23%+5.48%+15.05%-30.74%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Karuna Therapeutics, Inc. stock logo
KRTX
Karuna Therapeutics
$329.83
$327.01
$158.38
▼
$329.99
$12.58B1.18832,048 shsN/A
BeOne Medicines Ltd. - Sponsored ADR stock logo
ONC
BeOne Medicines
$412.35
-1.0%
$369.18
$253.95
▼
$424.73
$45.34B0.63322,642 shs84,293 shs
Royalty Pharma PLC stock logo
RPRX
Royalty Pharma
$68.67
-0.9%
$61.51
$37.31
▼
$70.37
$39.42B0.363.42 million shs1.44 million shs
Zoetis Inc. stock logo
ZTS
Zoetis
$83.61
-0.3%
$76.28
$68.77
▼
$132.49
$33.96B0.675.43 million shs1.72 million shs
7 Best Space Stocks to Own in 2026 Cover

The space race is growing fast, and you don’t have to have gotten in early on SpaceX to profit. This report shows seven space stocks you can buy today that may grow as rockets, satellites, defense, space internet, and new space technology become more important.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Karuna Therapeutics, Inc. stock logo
KRTX
Karuna Therapeutics
0.00%0.00%0.00%0.00%0.00%
BeOne Medicines Ltd. - Sponsored ADR stock logo
ONC
BeOne Medicines
0.00%+2.35%+12.87%+14.90%+13.86%
Royalty Pharma PLC stock logo
RPRX
Royalty Pharma
0.00%+2.99%+13.70%+16.59%+76.99%
Zoetis Inc. stock logo
ZTS
Zoetis
0.00%+5.23%+5.48%+15.05%-30.74%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Karuna Therapeutics, Inc. stock logo
KRTX
Karuna Therapeutics
0.00
N/AN/AN/A
BeOne Medicines Ltd. - Sponsored ADR stock logo
ONC
BeOne Medicines
3.00
Buy$440.576.97% Upside
Royalty Pharma PLC stock logo
RPRX
Royalty Pharma
3.11
Buy$63.29-7.80% Downside
Zoetis Inc. stock logo
ZTS
Zoetis
2.33
Hold$101.2521.41% Upside

Current Analyst Ratings Breakdown

Latest KRTX, ONC, RPRX, and ZTS Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
11/13/2026
BeOne Medicines Ltd. - Sponsored ADR stock logo
ONC
BeOne Medicines
Boost Price TargetOverweight$465.00 ➝ $476.00
11/11/2026
Royalty Pharma PLC stock logo
RPRX
Royalty Pharma
UpgradeHold ➝ Strong-Buy
11/6/2026
BeOne Medicines Ltd. - Sponsored ADR stock logo
ONC
BeOne Medicines
Initiated CoverageStrong-Buy
11/6/2026
BeOne Medicines Ltd. - Sponsored ADR stock logo
ONC
BeOne Medicines
Boost Price TargetOutperform$459.00 ➝ $465.00
11/6/2026
BeOne Medicines Ltd. - Sponsored ADR stock logo
ONC
BeOne Medicines
Reiterated RatingBuy$420.00 ➝ $448.00
11/6/2026
BeOne Medicines Ltd. - Sponsored ADR stock logo
ONC
BeOne Medicines
Boost Price TargetOverweight$415.00 ➝ $446.00
11/6/2026
BeOne Medicines Ltd. - Sponsored ADR stock logo
ONC
BeOne Medicines
Boost Price TargetMarket Outperform$405.00 ➝ $463.00
11/6/2026
BeOne Medicines Ltd. - Sponsored ADR stock logo
ONC
BeOne Medicines
Boost Price TargetOverweight$400.00 ➝ $435.00
11/6/2026
Zoetis Inc. stock logo
ZTS
Zoetis
Boost Price Target$83.00 ➝ $85.00
11/5/2026
BeOne Medicines Ltd. - Sponsored ADR stock logo
ONC
BeOne Medicines
Reiterated RatingBuy$470.00
11/5/2026
Royalty Pharma PLC stock logo
RPRX
Royalty Pharma
Boost Price TargetBuy$70.00 ➝ $78.00
(Data available from 11/16/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Karuna Therapeutics, Inc. stock logo
KRTX
Karuna Therapeutics
$654K19,239.07N/AN/A$33.24 per share9.92
BeOne Medicines Ltd. - Sponsored ADR stock logo
ONC
BeOne Medicines
$6.61B6.84$3.86 per share106.57$39.77 per share10.36
Royalty Pharma PLC stock logo
RPRX
Royalty Pharma
$2.38B16.56$4.73 per share14.51$16.83 per share4.08
Zoetis Inc. stock logo
ZTS
Zoetis
$9.49B3.57$7.53 per share11.08$7.56 per share11.03
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Karuna Therapeutics, Inc. stock logo
KRTX
Karuna Therapeutics
-$433.68M-$11.72N/AN/AN/AN/A-31.63%-30.38%N/A
BeOne Medicines Ltd. - Sponsored ADR stock logo
ONC
BeOne Medicines
$286.93M$7.8752.4130.04N/A13.86%19.04%10.70%N/A
Royalty Pharma PLC stock logo
RPRX
Royalty Pharma
$770.95M$1.2057.2511.901.3725.68%30.04%14.97%N/A
Zoetis Inc. stock logo
ZTS
Zoetis
$2.67B$5.8814.1813.131.2126.15%85.90%18.39%N/A

Latest KRTX, ONC, RPRX, and ZTS Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
11/5/2026Q3 2026
BeOne Medicines Ltd. - Sponsored ADR stock logo
ONC
BeOne Medicines
$2.34$3.64+$1.30$3.28$1.76 billion$1.89 billion
11/5/2026Q3 2026
Zoetis Inc. stock logo
ZTS
Zoetis
$1.51$1.75+$0.24$1.44$2.30 billion$2.39 billion
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Karuna Therapeutics, Inc. stock logo
KRTX
Karuna Therapeutics
N/AN/AN/AN/AN/A
BeOne Medicines Ltd. - Sponsored ADR stock logo
ONC
BeOne Medicines
N/AN/AN/AN/AN/A
Royalty Pharma PLC stock logo
RPRX
Royalty Pharma
$0.941.37%+24.01%78.33%5 Years
Zoetis Inc. stock logo
ZTS
Zoetis
$2.122.54%+20.11%36.05%14 Years

Latest KRTX, ONC, RPRX, and ZTS Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
10/16/2026
Royalty Pharma PLC stock logo
RPRX
Royalty Pharma
quarterly$0.23501.36%11/13/202611/13/202612/10/2026
10/8/2026
Zoetis Inc. stock logo
ZTS
Zoetis
quarterly$0.532.66%10/30/202610/30/202612/1/2026
(Data available from 1/1/2013 forward)
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Karuna Therapeutics, Inc. stock logo
KRTX
Karuna Therapeutics
N/A
19.31
19.31
BeOne Medicines Ltd. - Sponsored ADR stock logo
ONC
BeOne Medicines
0.14
3.55
3.19
Royalty Pharma PLC stock logo
RPRX
Royalty Pharma
0.77
1.29
1.29
Zoetis Inc. stock logo
ZTS
Zoetis
2.51
2.35
1.40

Institutional Ownership

CompanyInstitutional Ownership
Karuna Therapeutics, Inc. stock logo
KRTX
Karuna Therapeutics
N/A
BeOne Medicines Ltd. - Sponsored ADR stock logo
ONC
BeOne Medicines
48.55%
Royalty Pharma PLC stock logo
RPRX
Royalty Pharma
54.35%
Zoetis Inc. stock logo
ZTS
Zoetis
92.80%

Insider Ownership

CompanyInsider Ownership
Karuna Therapeutics, Inc. stock logo
KRTX
Karuna Therapeutics
13.20%
BeOne Medicines Ltd. - Sponsored ADR stock logo
ONC
BeOne Medicines
6.19%
Royalty Pharma PLC stock logo
RPRX
Royalty Pharma
18.84%
Zoetis Inc. stock logo
ZTS
Zoetis
0.22%
CompanyEmployeesShares OutstandingFree FloatOptionable
Karuna Therapeutics, Inc. stock logo
KRTX
Karuna Therapeutics
33938.15 million33.16 millionOptionable
BeOne Medicines Ltd. - Sponsored ADR stock logo
ONC
BeOne Medicines
12,000109.79 million102.99 millionOptionable
Royalty Pharma PLC stock logo
RPRX
Royalty Pharma
100573.60 million465.54 millionOptionable
Zoetis Inc. stock logo
ZTS
Zoetis
14,500406.32 million405.42 millionOptionable

Recent News About These Companies

Zoetis stock gains USDA license for 75-day itch treatment
Zoetis stock trades 2.69% above Wednesday's Xetra close
Zoetis Inc. $ZTS Position Lessened by Candriam S.C.A.
Zoetis (NYSE:ZTS) Price Target Raised to $85.00
What Zoetis (ZTS) Said on Its Q3 Earnings Call
UBS Sticks to Their Hold Rating for Zoetis (ZTS)
Zoetis stock lifts 2026 outlook after mixed third quarter

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
Karuna Therapeutics stock logo

Karuna Therapeutics NASDAQ:KRTX

Karuna Therapeutics, Inc., a clinical-stage biopharmaceutical company, creates and delivers transformative medicines for people living with psychiatric and neurological conditions. Its lead product candidate includes KarXT, an oral modulator of muscarinic receptors for the treatment of acute psychosis in patients with schizophrenia; and for the treatment of central nervous system disorders, such as negative and cognitive symptoms of schizophrenia and psychosis, as well as for the treatment of various peripheral tissues and dementia-related psychosis, including Alzheimer's disease. The company also focuses on developing other muscarinic-targeted drug candidates; and intends to develop lead candidature TRPC4/5 and KAR-2618 for the treatment of depressive disorder. Karuna Therapeutics, Inc. has a license agreement with Eli Lilly and Company, and Zai Lab (Shanghai) Co., Ltd; patent license agreement with PureTech Health LLC; and drug discovery partnership with Charles River Laboratories, as well as drug discovery collaboration with PsychoGenics, Inc. The company was formerly known as Karuna Pharmaceuticals, Inc. and changed its name to Karuna Therapeutics, Inc. in March 2019. Karuna Therapeutics, Inc. was incorporated in 2009 and is headquartered in Boston, Massachusetts.

BeOne Medicines stock logo

BeOne Medicines NASDAQ:ONC

$412.13 -4.41 (-1.06%)
As of 02:41 PM Eastern
This is a fair market value price provided by Massive. Learn more.

BeOne Medicines Ltd. is a global oncology company domiciled in Switzerland that is discovering and developing innovative treatments that are more affordable and accessible to cancer patients worldwide. The firm portfolio spanning hematology and solid tumors, BeOne is expediting development of its diverse pipeline of novel therapeutics through its internal capabilities and collaborations. The company was founded by Xiao Dong Wang and John V. Oyler on October 28, 2010 and is headquartered in Basel, Switzerland.

Royalty Pharma stock logo

Royalty Pharma NASDAQ:RPRX

$68.67 -0.65 (-0.93%)
As of 02:41 PM Eastern
This is a fair market value price provided by Massive. Learn more.

Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States. It is also involved in the identification, evaluation, and acquisition of royalties on various biopharmaceutical therapies. In addition, the company collaborates with innovators from academic institutions, research hospitals and not-for-profits, small and mid-cap biotechnology companies, and pharmaceutical companies. Its portfolio consists of royalties on approximately 35 commercial products and 14 development-stage product candidates that address various therapeutic areas, such as rare disease, cancer, neuroscience, immunology, respiratory, infectious disease, hematology, and diabetes. The company was founded in 1996 and is based in New York, New York.

Zoetis stock logo

Zoetis NYSE:ZTS

$83.56 -0.26 (-0.32%)
As of 02:41 PM Eastern
This is a fair market value price provided by Massive. Learn more.

Zoetis Inc. engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses. It also offers parasiticides, vaccines, dermatology, other pharmaceutical, anti-infectives, animal health diagnostics, and medicated feed additives. In addition, the company provides animal health diagnostics, including point-of-care diagnostic products, instruments and reagents, rapid immunoassay tests, reference laboratory kits and services, and blood glucose monitors; and other non-pharmaceutical products, which include nutritionals, as well as products and services in biodevices, genetic tests, and precision animal health. It markets its products to veterinarians, livestock producers, and pet owners. The company has collaboration Blacksmith Medicines, Inc. to discover and develop novel antibiotics for animal health. Zoetis Inc. was founded in 1952 and is headquartered in Parsippany, New Jersey.